IN2014DN09240A - - Google Patents
Info
- Publication number
- IN2014DN09240A IN2014DN09240A IN9240DEN2014A IN2014DN09240A IN 2014DN09240 A IN2014DN09240 A IN 2014DN09240A IN 9240DEN2014 A IN9240DEN2014 A IN 9240DEN2014A IN 2014DN09240 A IN2014DN09240 A IN 2014DN09240A
- Authority
- IN
- India
- Prior art keywords
- combination
- treatment
- 11beta
- medicament
- human
- Prior art date
Links
- 229940123967 11-beta-hydroxylase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229940075620 somatostatin analogue Drugs 0.000 abstract 1
- 239000002438 stress hormone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623117P | 2012-04-12 | 2012-04-12 | |
| PCT/EP2013/057515 WO2013153129A1 (en) | 2012-04-12 | 2013-04-10 | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09240A true IN2014DN09240A (enExample) | 2015-07-10 |
Family
ID=48289057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9240DEN2014 IN2014DN09240A (enExample) | 2012-04-12 | 2013-04-10 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9333234B2 (enExample) |
| EP (1) | EP2836228B1 (enExample) |
| JP (1) | JP6383352B2 (enExample) |
| KR (1) | KR102136214B1 (enExample) |
| CN (1) | CN104321074B (enExample) |
| AU (1) | AU2013246908B2 (enExample) |
| BR (1) | BR112014025058B1 (enExample) |
| CA (1) | CA2869442C (enExample) |
| ES (1) | ES2980806T3 (enExample) |
| IN (1) | IN2014DN09240A (enExample) |
| MX (1) | MX362533B (enExample) |
| RU (1) | RU2663455C2 (enExample) |
| WO (1) | WO2013153129A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2523731B1 (en) * | 2010-01-14 | 2018-10-24 | Novartis AG | Use of an adrenal hormone-modifying agent |
| PT3166596T (pt) * | 2014-07-07 | 2018-10-19 | Novartis Ag | Formas farmacêuticas |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| JP6765443B2 (ja) * | 2016-01-19 | 2020-10-07 | コーセプト セラピューティクス， インコーポレイテッド | 異所性クッシング症候群の鑑別診断 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140837A0 (en) * | 1998-07-30 | 2002-02-10 | Sod Conseils Rech Applic | Method of using lanreotide, a somatostatin analogue |
| CN1541102A (zh) * | 2001-04-09 | 2004-10-27 | 生长激素抑制素激动剂 | |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP2507234B1 (en) * | 2009-11-30 | 2014-03-12 | Novartis AG | Imidazole derivatives as aldosterone synthase inhibitors |
| EP2523731B1 (en) * | 2010-01-14 | 2018-10-24 | Novartis AG | Use of an adrenal hormone-modifying agent |
| WO2013131879A1 (en) * | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
-
2013
- 2013-04-10 RU RU2014145351A patent/RU2663455C2/ru active
- 2013-04-10 AU AU2013246908A patent/AU2013246908B2/en not_active Ceased
- 2013-04-10 US US14/391,416 patent/US9333234B2/en active Active
- 2013-04-10 CN CN201380027076.7A patent/CN104321074B/zh active Active
- 2013-04-10 KR KR1020147031324A patent/KR102136214B1/ko not_active Expired - Fee Related
- 2013-04-10 MX MX2014012321A patent/MX362533B/es active IP Right Grant
- 2013-04-10 CA CA2869442A patent/CA2869442C/en active Active
- 2013-04-10 IN IN9240DEN2014 patent/IN2014DN09240A/en unknown
- 2013-04-10 WO PCT/EP2013/057515 patent/WO2013153129A1/en not_active Ceased
- 2013-04-10 EP EP13720275.0A patent/EP2836228B1/en active Active
- 2013-04-10 ES ES13720275T patent/ES2980806T3/es active Active
- 2013-04-10 BR BR112014025058-8A patent/BR112014025058B1/pt not_active IP Right Cessation
- 2013-04-10 JP JP2015504946A patent/JP6383352B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014145351A (ru) | 2016-06-10 |
| EP2836228A1 (en) | 2015-02-18 |
| KR20150004831A (ko) | 2015-01-13 |
| BR112014025058B1 (pt) | 2022-07-12 |
| CN104321074B (zh) | 2017-09-08 |
| US9333234B2 (en) | 2016-05-10 |
| KR102136214B1 (ko) | 2020-07-22 |
| CA2869442C (en) | 2020-09-08 |
| JP6383352B2 (ja) | 2018-08-29 |
| AU2013246908A1 (en) | 2014-10-23 |
| CN104321074A (zh) | 2015-01-28 |
| US20150087588A1 (en) | 2015-03-26 |
| MX362533B (es) | 2019-01-23 |
| RU2663455C2 (ru) | 2018-08-06 |
| EP2836228B1 (en) | 2024-03-20 |
| AU2013246908B2 (en) | 2016-06-30 |
| ES2980806T3 (es) | 2024-10-03 |
| JP2015512923A (ja) | 2015-04-30 |
| WO2013153129A1 (en) | 2013-10-17 |
| MX2014012321A (es) | 2015-09-24 |
| CA2869442A1 (en) | 2013-10-17 |
| BR112014025058A2 (enExample) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012502161A1 (en) | Pharmaceutical formulations comprising pioglitazone and linagliptin | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MY188382A (en) | Spirocyclic inhibitors of cathepsin c | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| EA025518B9 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| IN2015DN00528A (enExample) | ||
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| MX2014012321A (es) | Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
| MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
| WO2014155268A3 (en) | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity | |
| MY159675A (en) | Clerodane derivatives for modulation of leukotriene receptor activity and related diseases | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis | |
| TH149179A (th) | องค์ประกอบทางเภสัชกรรม, รูปแบบเภสัชภัณฑ์, กระบวนการในการเตรียมองค์ประกอบ และรูปแบบดังกล่าว, วิธีการในการรักษา และการใช้องค์ประกอบและรูปแบบดังกล่าว |